Literature DB >> 11742497

High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance.

H A Cocker1, S M Hobbs, N Tiffin, K Pritchard-Jones, C R Pinkerton, L R Kelland.   

Abstract

The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas. (c) 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742497      PMCID: PMC2363993          DOI: 10.1054/bjoc.2001.2145

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  Regulation of p53 stability.

Authors:  M Ashcroft; K H Vousden
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

2.  Stabilization of the MDM2 oncoprotein by mutant p53.

Authors:  Y Peng; L Chen; C Li; W Lu; S Agrawal; J Chen
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter.

Authors:  T Léveillard; B Wasylyk
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

5.  P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.

Authors:  A C Taylor; L Shu; M K Danks; C A Poquette; S Shetty; M J Thayer; P J Houghton; L C Harris
Journal:  Med Pediatr Oncol       Date:  2000-08

6.  Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins.

Authors:  S Hobbs; S Jitrapakdee; J C Wallace
Journal:  Biochem Biophys Res Commun       Date:  1998-11-18       Impact factor: 3.575

7.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

8.  Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

Authors:  H S Chan; P S Thorner; G Haddad; V Ling
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

9.  Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.

Authors:  H A Cocker; C R Pinkerton; L R Kelland
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.

Authors:  A Suzuki; M Toi; Y Yamamoto; S Saji; M Muta; T Tominaga
Journal:  Jpn J Cancer Res       Date:  1998-02
View more
  8 in total

1.  Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.

Authors:  Wanqing Liu; Lijun He; Jacqueline Ramírez; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

2.  Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old.

Authors:  Nicholas Olson; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Barbara Alemar; Britta Weigelt; Joel Lefferts; Konstantinos Linos
Journal:  Int J Surg Pathol       Date:  2019-12-04       Impact factor: 1.271

3.  Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.

Authors:  Guido Seitz; Steven W Warmann; Christian O Vokuhl; Heike Heitmann; Claudia Treuner; Ivo Leuschner; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2007-05       Impact factor: 2.003

4.  Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.

Authors:  X Xie; G Lozano; Z H Siddik
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

5.  Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.

Authors:  Joshua T Kowalczyk; Xiaolin Wan; Edjay R Hernandez; Ruibai Luo; Gaelyn C Lyons; Kelli M Wilson; Devorah C Gallardo; Kristine A Isanogle; Christina M Robinson; Arnulfo Mendoza; Christine M Heske; Jinqui-Qiu Chen; Xiaoling Luo; Alexander E Kelly; Simone Difilippantinio; Robert W Robey; Craig J Thomas; Dan L Sackett; Deborah K Morrison; Paul A Randazzo; Lisa M Miller Jenkins; Marielle E Yohe
Journal:  Mol Cancer Ther       Date:  2020-11-06       Impact factor: 6.009

6.  A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin.

Authors:  H-J Tang; D Qian; V K Sondak; S Stachura; J Lin
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

Review 7.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Authors:  Jahangir Abdi; Guoan Chen; Hong Chang
Journal:  Oncotarget       Date:  2013-12

8.  The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells.

Authors:  Jenna Susan Bleloch; André du Toit; Liezl Gibhard; Serah Kimani; Reyna Deeya Ballim; Minkyu Lee; Angelique Blanckenberg; Selwyn Mapolie; Lubbe Wiesner; Ben Loos; Sharon Prince
Journal:  Cell Death Discov       Date:  2019-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.